TrialJournal of inherited metabolic disease2025

Extended long-term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha-mannosidosis.

Nathalie Guffon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.